NO20064309L - Azabicyklo(3.1.0)heksanderivater anvendelige som modulatorer for dopamin D3 receptorer - Google Patents

Azabicyklo(3.1.0)heksanderivater anvendelige som modulatorer for dopamin D3 receptorer

Info

Publication number
NO20064309L
NO20064309L NO20064309A NO20064309A NO20064309L NO 20064309 L NO20064309 L NO 20064309L NO 20064309 A NO20064309 A NO 20064309A NO 20064309 A NO20064309 A NO 20064309A NO 20064309 L NO20064309 L NO 20064309L
Authority
NO
Norway
Prior art keywords
group
4alkyl
alkyl
cyano
halogen
Prior art date
Application number
NO20064309A
Other languages
English (en)
Norwegian (no)
Inventor
Romano Di Fabio
Luca Arista
Luca Tarsi
Silvia Terreni
Anna Maria Capelli
Gabriella Gentile
Fabrizio Micheli
Dieter Hamprecht
Giorgio Bonanomi
Federica Damiani
Giovanna Tedesco
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0403990A external-priority patent/GB0403990D0/en
Priority claimed from GB0404083A external-priority patent/GB0404083D0/en
Priority claimed from GB0417120A external-priority patent/GB0417120D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20064309L publication Critical patent/NO20064309L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20064309A 2004-02-23 2006-09-22 Azabicyklo(3.1.0)heksanderivater anvendelige som modulatorer for dopamin D3 receptorer NO20064309L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0403990A GB0403990D0 (en) 2004-02-23 2004-02-23 Compounds
GB0404083A GB0404083D0 (en) 2004-02-24 2004-02-24 Compounds
GB0417120A GB0417120D0 (en) 2004-07-30 2004-07-30 Compounds
PCT/EP2005/001940 WO2005080382A1 (en) 2004-02-23 2005-02-21 Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors

Publications (1)

Publication Number Publication Date
NO20064309L true NO20064309L (no) 2006-11-23

Family

ID=34890800

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064309A NO20064309L (no) 2004-02-23 2006-09-22 Azabicyklo(3.1.0)heksanderivater anvendelige som modulatorer for dopamin D3 receptorer

Country Status (26)

Country Link
US (3) US7855298B2 (de)
EP (3) EP2070922B1 (de)
JP (1) JP4960217B2 (de)
KR (1) KR101143718B1 (de)
CN (1) CN1946714B (de)
AR (1) AR047890A1 (de)
AT (3) ATE542816T1 (de)
AU (2) AU2005215918C1 (de)
BR (1) BRPI0507945A (de)
CA (1) CA2557115C (de)
CY (3) CY1109854T1 (de)
DE (1) DE602005018190D1 (de)
DK (3) DK2070922T3 (de)
ES (2) ES2380990T3 (de)
HK (1) HK1103016A1 (de)
HR (3) HRP20100114T1 (de)
IL (1) IL177184A0 (de)
MA (1) MA28438B1 (de)
NO (1) NO20064309L (de)
PE (1) PE20051173A1 (de)
PL (3) PL2070922T3 (de)
PT (3) PT1745040E (de)
RU (1) RU2434011C2 (de)
SI (3) SI2070922T1 (de)
TW (1) TW200538113A (de)
WO (1) WO2005080382A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1946714B (zh) * 2004-02-23 2011-06-15 葛兰素集团有限公司 用作多巴胺d3受体调节剂的氮杂二环(3.1.0)己烷衍生物
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
ATE484502T1 (de) 2005-06-14 2010-10-15 Glaxo Group Ltd Neue verbindungen
GB0512099D0 (en) 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
WO2007006117A1 (en) * 2005-07-13 2007-01-18 Nicogen Inc. Novel cyp2a6 inhibitors
US20070082940A1 (en) * 2005-07-27 2007-04-12 Phil Skolnick Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
GB0517175D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517191D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
ATE487715T1 (de) * 2005-08-22 2010-11-15 Glaxo Group Ltd Triazolderivate als modulatoren von dopamin-d3- rezeptoren
GB0703387D0 (en) * 2007-02-21 2007-03-28 Glaxo Group Ltd Novel compounds
DE602007012531D1 (de) * 2006-04-03 2011-03-31 Glaxo Group Ltd Azabicycloä3.1.0ühexanderivate als modulatoren von dopamin-d3-rezeptoren
EP2007750B1 (de) * 2006-04-03 2013-08-21 Glaxo Group Limited Azabicyclo[3.1.0] hexylderivate als modulatoren von dopamin-d3-rezeptoren
GB0607899D0 (en) 2006-04-03 2006-05-31 Glaxo Group Ltd Process for preparing heterocyclic derivatives
US8222266B2 (en) * 2006-04-03 2012-07-17 Glaxo Group Limited Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors
GB0608452D0 (en) * 2006-04-27 2006-06-07 Glaxo Group Ltd Novel compounds
US20080045725A1 (en) 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
GB0616574D0 (en) * 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds
US8138377B2 (en) 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
WO2008153937A2 (en) * 2007-06-06 2008-12-18 Dov Pharmaceutical, Inc. Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
GB0719235D0 (en) * 2007-10-02 2007-11-14 Glaxo Group Ltd Novel compounds
GB0719234D0 (en) * 2007-10-02 2007-11-14 Glaxo Group Ltd Novel compounds
MX2010014500A (es) 2008-06-24 2011-05-30 Codexis Inc Procedimientos biocataliticos para la preparacion de compuestos de prolina biciclica fusionada sustancialmente estereomericamente puros.
PE20110843A1 (es) 2008-09-22 2011-12-08 Cayman Chem Co Derivados de 5-(1h-imidazol-5-il)-2-fenilpirimidina, como inhibidores de prostaglandina d sintasa hematopoyetica
BR112012000657A2 (pt) 2009-06-26 2016-11-16 Panacea Biotec Ltd novos azabicilohexanos
JP2016535796A (ja) * 2013-11-11 2016-11-17 ユーシミクス・バイオサイエンス・インコーポレイテッドEuthymics Bioscience,Inc. 新規な方法
AU2016303558B2 (en) 2015-08-05 2020-08-06 Indivior Uk Limited Dopamine D3 receptor antagonists having a bicyclo moiety
JP7250405B2 (ja) 2018-01-26 2023-04-03 塩野義製薬株式会社 ドーパミンd3受容体拮抗作用を有する環式化合物
BR112022026201A2 (pt) 2020-06-22 2023-01-17 Corcept Therapeutics Inc Antagonistas do receptor de glicocorticoide de indazol quaternários
US20230242514A1 (en) * 2021-12-21 2023-08-03 Corcept Therapeutics Incorporated Bicyclic indazole glucocorticoid receptor antagonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR022228A1 (es) * 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para la preparar dicha composicion
GB0015562D0 (en) * 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
CA2428844A1 (en) * 2000-11-14 2002-05-23 Michael Stewart Hadley Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
SI1440059T1 (sl) 2001-10-22 2008-08-31 Pfizer Prod Inc Derivati 3-azabiciklo(3.1.0)heksana kot antagonisti opioidnega receptorja
RU2352568C9 (ru) * 2002-08-09 2009-06-27 Астразенека Аб [1,2,4]оксадиазолы (варианты), способ их получения, фармацевтическая композиция и способ ингибирования активации метаботропных глютаматных рецепторов-5
CN1946714B (zh) * 2004-02-23 2011-06-15 葛兰素集团有限公司 用作多巴胺d3受体调节剂的氮杂二环(3.1.0)己烷衍生物
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507602D0 (en) 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
ATE484502T1 (de) 2005-06-14 2010-10-15 Glaxo Group Ltd Neue verbindungen
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
GB0517191D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517175D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
ATE487715T1 (de) * 2005-08-22 2010-11-15 Glaxo Group Ltd Triazolderivate als modulatoren von dopamin-d3- rezeptoren
EP2007750B1 (de) 2006-04-03 2013-08-21 Glaxo Group Limited Azabicyclo[3.1.0] hexylderivate als modulatoren von dopamin-d3-rezeptoren
GB0616574D0 (en) * 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
EP1745040B9 (de) 2010-06-02
HK1103016A1 (en) 2007-12-14
TW200538113A (en) 2005-12-01
CN1946714A (zh) 2007-04-11
PL2060570T3 (pl) 2012-06-29
DK1745040T3 (da) 2010-04-12
EP2070922A1 (de) 2009-06-17
EP1745040A1 (de) 2007-01-24
US8283474B2 (en) 2012-10-09
EP2060570B1 (de) 2012-01-25
DE602005018190D1 (de) 2010-01-21
EP2060570A2 (de) 2009-05-20
US7855298B2 (en) 2010-12-21
BRPI0507945A (pt) 2007-07-24
CA2557115C (en) 2012-10-02
JP2007523208A (ja) 2007-08-16
RU2434011C2 (ru) 2011-11-20
ATE451364T1 (de) 2009-12-15
SI1745040T1 (sl) 2010-04-30
CY1112011T1 (el) 2015-11-04
JP4960217B2 (ja) 2012-06-27
US8263782B2 (en) 2012-09-11
SI2060570T1 (sl) 2012-05-31
IL177184A0 (en) 2006-12-10
EP1745040B1 (de) 2009-12-09
US20070142438A1 (en) 2007-06-21
CA2557115A1 (en) 2005-09-01
AU2005215918B2 (en) 2009-06-11
HRP20110781T1 (hr) 2011-11-30
US20100160336A1 (en) 2010-06-24
HRP20120281T1 (hr) 2012-04-30
ATE520686T1 (de) 2011-09-15
ES2337590T3 (es) 2010-04-27
PE20051173A1 (es) 2006-02-14
EP2070922B1 (de) 2011-08-17
AU2005215918A1 (en) 2005-09-01
HRP20100114T1 (hr) 2010-04-30
CN1946714B (zh) 2011-06-15
ES2380990T3 (es) 2012-05-22
EP2060570A3 (de) 2009-06-03
AU2005215918C1 (en) 2010-01-21
WO2005080382A1 (en) 2005-09-01
AU2009212887A1 (en) 2009-09-24
PL2070922T3 (pl) 2012-01-31
SI2070922T1 (sl) 2011-12-30
DK2070922T3 (da) 2011-11-28
PT2060570E (pt) 2012-05-07
DK2060570T3 (da) 2012-04-30
PL1745040T3 (pl) 2010-05-31
AR047890A1 (es) 2006-03-01
ATE542816T1 (de) 2012-02-15
CY1113029T1 (el) 2016-04-13
PT1745040E (pt) 2010-03-08
CY1109854T1 (el) 2014-09-10
PT2070922E (pt) 2011-11-24
KR101143718B1 (ko) 2012-07-05
US20100152195A1 (en) 2010-06-17
RU2006133909A (ru) 2008-03-27
MA28438B1 (fr) 2007-02-01
KR20060127991A (ko) 2006-12-13

Similar Documents

Publication Publication Date Title
NO20064309L (no) Azabicyklo(3.1.0)heksanderivater anvendelige som modulatorer for dopamin D3 receptorer
ATE487715T1 (de) Triazolderivate als modulatoren von dopamin-d3- rezeptoren
ATE493404T1 (de) Azabicyclo-(3,1,0)-hexan-derivate als modulatoren von dopamin-d3-rezeptoren
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
ATE484502T1 (de) Neue verbindungen
CO6251248A2 (es) Compuestos de tiazolopiridina como moduladores de sirtuina
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR060237A1 (es) Compuesto de 3-azabiciclo[3.1.0]hexano como moduladores del receptor de dopamina d3, su uso para la preparacion de un medicamento para el tratamiento de afecciones psicoticas y composicion farmaceutica que lo comprende.
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
DE602006011725D1 (de) 3-triazolylthioalkyl-3-azabicyclo ä3.1.0ühexane und ihre verwendung als liganden des dopamin-d3-rezeptors
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
NO20063355L (no) Nye trisykliske spiroderivater som modulatorer for kemokinreseptoraktivitet
MX2009004780A (es) Derivados de quiniclidina de acido (hetero) arilcicloheptano carboxilico como antagonistas del receptor muscarinico.
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
AR067412A1 (es) Moduladores de propiedades farmaceuticas de productos terapeuticos
MY153042A (en) Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
HK1142604A1 (en) Quinolines and their therapeutic use
RS52321B (en) INDUL-2-S DISOBSTITUTED DERIVATIVES IN POSITION 3, THEIR PRODUCTION AND THEIR USE IN TREATMENT
AR077367A1 (es) 2- carboxamida -cicloamino-ureas sustituidas
ATE512142T1 (de) Pyrimidin- und chinazolinderivate als modulatoren der somatostatin-rezeptor aktivität
IN2012DN02871A (de)
MX2012008147A (es) Derivados de pirrazolopiridina.
ATE539053T1 (de) Azabicyclo ä3. 1. 0ü-hexylderivate als modulatoren von dopamin-d3-rezeptoren
ATE452636T1 (de) 3-azabicycloä4.1.0üheptan-derivate zur behandlung von depressionen
NO20084415L (no) Azabicyklo[3.1.0]heksylderivater som modulatorer av dopamin D3 receptorer

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXO GROUP LTD, GB

FC2A Withdrawal, rejection or dismissal of laid open patent application